Hai Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hai Li has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Jinzhong Cao
First Clinical Medical College, General Hospital of Ningxia Medical University, Yinchuan, China
5 shared publicationsShaohua Hou
Department of Anal-Colorectal Surgery, General Hospital of Ningxia Medical University, Yinchuan, China
5 shared publications- Tao Jiang
Department of Anal-Colorectal Surgery, General Hospital of Ningxia Medical University, Yinchuan, China
5 shared publications Zijing Wang
First Clinical Medical College, General Hospital of Ningxia Medical University, Yinchuan, China
5 shared publicationsXi Chen
Department of Obstetrics and Gynecology, Gansu Provincial Clinical Research Center for Gynecological Oncology, The First Clinical Medical College of Lanzhou University, Lanzhou, China
4 shared publicationsZhanyuan Sun
First Clinical Medical College, General Hospital of Ningxia Medical University, Yinchuan, China
4 shared publications
Latest Publications
- Open Access
- 20 September 2026
- Published by Springer Nature in Scientific Reports
Integrated multi-omics analyses reveal the role of PAXX in colorectal cancer progression and the tumor immune microenvironment
PAXX is a DNA double-strand break repair factor involved in classical non-homologous end joining. Although elevated PAXX expression has been reported in colon cancer, its functional role and downstream mechanisms in colorectal cancer (CRC) remain incompletely defined. This study investigated the role of PAXX in CRC progression and its association with the tumor immune microenvironment. Public transcriptomic, proteomic, genomic, and single-cell datasets were integrated with clinical sample validation and functional experiments. Stable PAXX knockdown models were used to assess CRC cell proliferation, migration, invasion, and xenograft growth. RNA sequencing, Western blotting, and EGF-mediated rescue experiments were performed to evaluate EMT-related alterations and MAPK/ERK signaling. PAXX was upregulated in CRC tissues and cell lines and was associated with poorer overall survival, although its standalone prognostic discrimination was limited. PAXX knockdown suppressed proliferation, migration, invasion, and xenograft growth and attenuated EMT-related molecular alterations. RNA-seq and enrichment analyses showed coordinated suppression of MAPK signaling and EMT-related transcriptional programs following PAXX depletion. Consistently, p-MEK1/2 and p-ERK1/2 levels were reduced without substantial changes in total MEK1/2 or ERK1/2. EGF-mediated pathway stimulation restored MEK/ERK phosphorylation and partially reversed the inhibitory effects of PAXX depletion on malignant phenotypes and EMT-related alterations. High PAXX expression was also associated with distinct immune and stromal characteristics, while single-cell and CellChat analyses identified heterogeneous PAXX expression and predicted HGF- and VEGF-related intercellular communication. PAXX is associated with CRC progression and unfavorable prognosis. Functional and rescue experiments support MAPK/ERK signaling as a partial mediator of PAXX-associated malignant phenotypes. Immune and intercellular communication findings remain computationally inferred and require further validation.
- 20 September 2026
- Published by Springer Nature in Scientific Reports
Open AccessIntegrated multi-omics analyses reveal the role of PAXX in colorectal cancer progression and the tumor immune microenvironment
PAXX is a DNA double-strand break repair factor involved in classical non-homologous end joining. Although elevated PAXX expression has been reported in colon cancer, its functional role and downstream mechanisms in colorectal cancer (CRC) remain incompletely defined. This study investigated the role of PAXX in CRC progression and its association with the tumor immune microenvironment. Public transcriptomic, proteomic, genomic, and single-cell datasets were integrated with clinical sample validation and functional experiments. Stable PAXX knockdown models were used to assess CRC cell proliferation, migration, invasion, and xenograft growth. RNA sequencing, Western blotting, and EGF-mediated rescue experiments were performed to evaluate EMT-related alterations and MAPK/ERK signaling. PAXX was upregulated in CRC tissues and cell lines and was associated with poorer overall survival, although its standalone prognostic discrimination was limited. PAXX knockdown suppressed proliferation, migration, invasion, and xenograft growth and attenuated EMT-related molecular alterations. RNA-seq and enrichment analyses showed coordinated suppression of MAPK signaling and EMT-related transcriptional programs following PAXX depletion. Consistently, p-MEK1/2 and p-ERK1/2 levels were reduced without substantial changes in total MEK1/2 or ERK1/2. EGF-mediated pathway stimulation restored MEK/ERK phosphorylation and partially reversed the inhibitory effects of PAXX depletion on malignant phenotypes and EMT-related alterations. High PAXX expression was also associated with distinct immune and stromal characteristics, while single-cell and CellChat analyses identified heterogeneous PAXX expression and predicted HGF- and VEGF-related intercellular communication. PAXX is associated with CRC progression and unfavorable prognosis. Functional and rescue experiments support MAPK/ERK signaling as a partial mediator of PAXX-associated malignant phenotypes. Immune and intercellular communication findings remain computationally inferred and require further validation.
- Open Access
- 3 March 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Integrative machine learning models reveal immune and metabolic signatures predictive of colorectal cancer prognosis
Background: The progression of colorectal cancer (CRC) is profoundly shaped by immune and metabolic dysregulation within the tumor microenvironment (TME). This study aimed to develop an immune–metabolism-related gene (IMRG)-based prognostic model and experimentally validate its key molecular drivers. Methods: Transcriptomic and clinical data from the TCGA and GEO cohorts were analyzed to identify differentially expressed IMRGs. Molecular subtypes were defined using non-negative matrix factorization (NMF) clustering, and a machine learning–based prognostic model integrating 101 algorithmic combinations was constructed and validated. Gene Set Enrichment Analysis (GSEA), immune infiltration profiling, and drug sensitivity analyses were performed to elucidate biological and immunological differences. IL20RB, identified as a hub IMRG, was further validated through qRT–PCR, Western blotting, and IHC. Its functional role was assessed using CCK-8, wound-healing, and Transwell assays. Results: NMF clustering revealed two distinct molecular subtypes of CRC with divergent survival outcomes and immune characteristics. The 4-gene IMRG-based model demonstrated robust prognostic performance (C-index = 0.657) and was externally validated in a GEO cohort (AUC up to 0.824 for 1-, 3-, and 5-year survival). GSEA showed that the high-risk group was enriched for complement/coagulation cascades and extracellular matrix remodeling, whereas the low-risk group was enriched for metabolic programs including butanoate metabolism and the TCA cycle. Immune profiling indicated increased CD8⁺ T-cell infiltration in the high-risk group and a distinct immune checkpoint landscape, with most checkpoints elevated in the low-risk group, while ADORA2A, TNFRSF25 and CD276 were relatively higher in the high-risk group. Experimental analyses confirmed that IL20RB was significantly upregulated in CRC tissues and cell lines, and its silencing markedly inhibited CRC cell proliferation, migration, and invasion, consistent with its predicted oncogenic role. Conclusion: This integrative transcriptomic and computational analysis combined with machine learning and experimental validation identified IMRGs—particularly IL20RB—as critical mediators of CRC progression. The proposed IMRG-based prognostic model offers a robust framework for patient risk stratification, immune landscape characterization, and therapeutic targeting in CRC.
- 3 March 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessIntegrative machine learning models reveal immune and metabolic signatures predictive of colorectal cancer prognosis
Background: The progression of colorectal cancer (CRC) is profoundly shaped by immune and metabolic dysregulation within the tumor microenvironment (TME). This study aimed to develop an immune–metabolism-related gene (IMRG)-based prognostic model and experimentally validate its key molecular drivers. Methods: Transcriptomic and clinical data from the TCGA and GEO cohorts were analyzed to identify differentially expressed IMRGs. Molecular subtypes were defined using non-negative matrix factorization (NMF) clustering, and a machine learning–based prognostic model integrating 101 algorithmic combinations was constructed and validated. Gene Set Enrichment Analysis (GSEA), immune infiltration profiling, and drug sensitivity analyses were performed to elucidate biological and immunological differences. IL20RB, identified as a hub IMRG, was further validated through qRT–PCR, Western blotting, and IHC. Its functional role was assessed using CCK-8, wound-healing, and Transwell assays. Results: NMF clustering revealed two distinct molecular subtypes of CRC with divergent survival outcomes and immune characteristics. The 4-gene IMRG-based model demonstrated robust prognostic performance (C-index = 0.657) and was externally validated in a GEO cohort (AUC up to 0.824 for 1-, 3-, and 5-year survival). GSEA showed that the high-risk group was enriched for complement/coagulation cascades and extracellular matrix remodeling, whereas the low-risk group was enriched for metabolic programs including butanoate metabolism and the TCA cycle. Immune profiling indicated increased CD8⁺ T-cell infiltration in the high-risk group and a distinct immune checkpoint landscape, with most checkpoints elevated in the low-risk group, while ADORA2A, TNFRSF25 and CD276 were relatively higher in the high-risk group. Experimental analyses confirmed that IL20RB was significantly upregulated in CRC tissues and cell lines, and its silencing markedly inhibited CRC cell proliferation, migration, and invasion, consistent with its predicted oncogenic role. Conclusion: This integrative transcriptomic and computational analysis combined with machine learning and experimental validation identified IMRGs—particularly IL20RB—as critical mediators of CRC progression. The proposed IMRG-based prognostic model offers a robust framework for patient risk stratification, immune landscape characterization, and therapeutic targeting in CRC.
- 24 February 2026
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 123, 108981
Prognostic signature and immune microenvironment characterization in colorectal cancer based on interleukin-related genes
- 24 February 2026
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 123, 108981
Prognostic signature and immune microenvironment characterization in colorectal cancer based on interleukin-related genes
- Open Access
- 9 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
PFDN2 stabilizes PYCR2 to activate Wnt/β-catenin signaling and promote colorectal cancer progression
Colorectal cancer (CRC) progression entails coordinated gene dysregulation and rewiring of signaling networks. Here, we investigated whether prefoldin subunit 2 (PFDN2) contributes to CRC progression by stabilizing pyrroline-5-carboxylate reductase 2 (PYCR2) and thereby modulating Wnt/β-catenin signaling. Integrated analyses of TCGA-COAD/READ and other public datasets showed that PFDN2 and PYCR2 are upregulated in CRC, positively correlated, and associated with poorer prognosis. These findings were corroborated in a 30-pair immunohistochemistry (IHC) cohort, and target modulation was confirmed by quantitative real-time PCR and Western blotting. Gain- and loss-of-function studies showed that PFDN2 promotes, whereas its knockdown suppresses, CRC cell proliferation and migration in vitro; in vivo, PFDN2 silencing reduced xenograft growth and Ki-67/β-catenin expression. PYCR2 was likewise elevated in CRC, linked to adverse clinicopathologic features, and enhanced proliferative and migratory phenotypes. Mechanistically, co-immunoprecipitation and immunofluorescence analyses revealed a PFDN2–PYCR2 interaction with predominantly cytoplasmic colocalization. PFDN2 manipulation altered PYCR2 protein but not mRNA levels; cycloheximide chase and MG132 rescue experiments indicated that PFDN2 stabilizes PYCR2 by limiting proteasome-dependent degradation. PFDN2 or PYCR2 depletion reduced TOP/FOPflash reporter activity, nuclear β-catenin accumulation, and expression of canonical Wnt targets, whereas PYCR2 re-expression partially restored these readouts and migratory capacity in PFDN2-silenced cells. Pharmacologic inhibition of canonical Wnt/β-catenin signaling attenuated the pro-proliferative and pro-migratory effects of PFDN2 or PYCR2 overexpression. The PFDN2–PYCR2–Wnt/β-catenin axis appears to be involved in CRC progression, and both proteins may have potential value as prognostic biomarkers and as candidates for further investigation as therapeutic targets.
- 9 February 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessPFDN2 stabilizes PYCR2 to activate Wnt/β-catenin signaling and promote colorectal cancer progression
Colorectal cancer (CRC) progression entails coordinated gene dysregulation and rewiring of signaling networks. Here, we investigated whether prefoldin subunit 2 (PFDN2) contributes to CRC progression by stabilizing pyrroline-5-carboxylate reductase 2 (PYCR2) and thereby modulating Wnt/β-catenin signaling. Integrated analyses of TCGA-COAD/READ and other public datasets showed that PFDN2 and PYCR2 are upregulated in CRC, positively correlated, and associated with poorer prognosis. These findings were corroborated in a 30-pair immunohistochemistry (IHC) cohort, and target modulation was confirmed by quantitative real-time PCR and Western blotting. Gain- and loss-of-function studies showed that PFDN2 promotes, whereas its knockdown suppresses, CRC cell proliferation and migration in vitro; in vivo, PFDN2 silencing reduced xenograft growth and Ki-67/β-catenin expression. PYCR2 was likewise elevated in CRC, linked to adverse clinicopathologic features, and enhanced proliferative and migratory phenotypes. Mechanistically, co-immunoprecipitation and immunofluorescence analyses revealed a PFDN2–PYCR2 interaction with predominantly cytoplasmic colocalization. PFDN2 manipulation altered PYCR2 protein but not mRNA levels; cycloheximide chase and MG132 rescue experiments indicated that PFDN2 stabilizes PYCR2 by limiting proteasome-dependent degradation. PFDN2 or PYCR2 depletion reduced TOP/FOPflash reporter activity, nuclear β-catenin accumulation, and expression of canonical Wnt targets, whereas PYCR2 re-expression partially restored these readouts and migratory capacity in PFDN2-silenced cells. Pharmacologic inhibition of canonical Wnt/β-catenin signaling attenuated the pro-proliferative and pro-migratory effects of PFDN2 or PYCR2 overexpression. The PFDN2–PYCR2–Wnt/β-catenin axis appears to be involved in CRC progression, and both proteins may have potential value as prognostic biomarkers and as candidates for further investigation as therapeutic targets.
- Open Access
- 8 January 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
The miR-181d-5p/SPP1 axis inhibits the migration and invasion of colorectal cancer via the RhoA patyway
Colorectal cancer (CRC), as the most common malignant tumor, seriously threatens human’s life and safety. Evidence suggests that microRNAs (miRNAs) exhibit an essential role in regulating the occurrence and development of CRC, while the detailed effects and possible mechanisms remain to be further explored. In the present study, a new tumor suppressor function of miR-181d-5p was disclosed in CRC. The expression of miR-181d-5p was obviously decreased in CRC tissues and cell lines. In addition, up-regulation of miR-181d-5p suppressed cell viability, migration, invasion, and epithelial-mesenchymal transition (EMT) progress in CRC cells detected by cell transfection, CCK-8, wound healing, transwell migration and western blot assays. Moreover, secreted phosphoprotein 1 (SPP1) was verified as a direct target of miR-181d-5p by binding its 3’-UTR, and confirmed by dual-luciferase reporter assay. Additionally, SPP1 was remarkably increased in CRC tissues and CC cell lines, and was negatively associated with miR-181d-5p expression. Furthermore, over-expression of SPP1 partially restored the inhibitory effects of up-regulated miR-181d-5p on cell viability, migration and EMT progress in CRC cells by modulating RhoA pathway. Finally, up-regulated miR-181d-5p inhibited the tumorigenesis in nude mice by regulating SPP1 mediated with RhoA pathway. To conclude, miR-181d-5p might serve as an effective target for the treatment of patients with CRC.
- 8 January 2026
- Published by Springer Nature in Scientific Reports
- Vol. 16 (1)
Open AccessThe miR-181d-5p/SPP1 axis inhibits the migration and invasion of colorectal cancer via the RhoA patyway
Colorectal cancer (CRC), as the most common malignant tumor, seriously threatens human’s life and safety. Evidence suggests that microRNAs (miRNAs) exhibit an essential role in regulating the occurrence and development of CRC, while the detailed effects and possible mechanisms remain to be further explored. In the present study, a new tumor suppressor function of miR-181d-5p was disclosed in CRC. The expression of miR-181d-5p was obviously decreased in CRC tissues and cell lines. In addition, up-regulation of miR-181d-5p suppressed cell viability, migration, invasion, and epithelial-mesenchymal transition (EMT) progress in CRC cells detected by cell transfection, CCK-8, wound healing, transwell migration and western blot assays. Moreover, secreted phosphoprotein 1 (SPP1) was verified as a direct target of miR-181d-5p by binding its 3’-UTR, and confirmed by dual-luciferase reporter assay. Additionally, SPP1 was remarkably increased in CRC tissues and CC cell lines, and was negatively associated with miR-181d-5p expression. Furthermore, over-expression of SPP1 partially restored the inhibitory effects of up-regulated miR-181d-5p on cell viability, migration and EMT progress in CRC cells by modulating RhoA pathway. Finally, up-regulated miR-181d-5p inhibited the tumorigenesis in nude mice by regulating SPP1 mediated with RhoA pathway. To conclude, miR-181d-5p might serve as an effective target for the treatment of patients with CRC.
- Open Access
- 5 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1671148
Intratumor heterogeneity score reveals immune landscape and survival stratification in colorectal cancer
Background: Intratumor heterogeneity (ITH), a critical driver of tumor evolution and immune evasion, remains inadequately characterized at the transcriptomic level in colorectal cancer (CRC), and its clinical implications are not yet fully understood. Methods: We integrated transcriptomic datasets from TCGA-COAD/READ and two independent GEO cohorts (GSE40967 and GSE87211) to develop an RNA-seq–based ITH score using the DEPTH2 algorithm and to con0struct an ITH-related gene (ITRG) prognostic model. A unified cutoff value of 0.64 was established to stratify patients into high- and low-ITH groups. Using 52 survival-associated ITRGs, we generated a nine-gene prognostic signature selected from 101 distinct combinations of feature selection techniques and modeling algorithms and validated its performance in two external datasets. The tumor microenvironment and potential responsiveness to immune checkpoint inhibitors were evaluated using ssGSEA, ESTIMATE, and TIDE algorithms. SHAP analysis, together with in vitro and in vivo experiments, was employed to identify and functionally validate key regulatory genes. Results: Patients in the high-ITH group had markedly poorer overall survival (OS) than those in the low-ITH group. The ITH score correlated strongly with aggressive clinical features, including T3/4 invasion depth, N1/2 nodal status, and AJCC stage III. The nine-gene prognostic signature demonstrated consistent predictive capability across the TCGA training cohort and both GEO validation cohorts. In TCGA, the model yielded time-dependent AUCs of 0.669, 0.664, and 0.645 for 1-, 3-, and 5-year OS, respectively, and retained its status as an independent prognostic indicator in multivariate Cox regression analysis; in GSE40967 and GSE87211, the corresponding AUCs ranged from 0.544–0.573 and 0.648–0.744. The high-risk subgroup was characterized by a stromal immune phenotype enriched with cancer-associated fibroblasts and macrophages, elevated expression of multiple immune checkpoints, increased TIDE scores, and higher tumor mutational burden. SHAP analysis identified IL20RB as the top risk-associated gene, whose knockdown significantly suppressed CRC cell proliferation, migration, invasion, and tumorigenicity in vitro and in vivo . Conclusion: This study introduces and validates a transcriptomic ITH score and a nine-gene ITRG-based prognostic model that delineate the immune landscape and enables effective survival stratification in CRC, complementing the limitations of current staging systems. Additionally, IL20RB is highlighted as a promising therapeutic target, supporting the development of personalized immuno-targeted combination therapies in CRC.
- 5 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1671148
Open AccessIntratumor heterogeneity score reveals immune landscape and survival stratification in colorectal cancer
Background: Intratumor heterogeneity (ITH), a critical driver of tumor evolution and immune evasion, remains inadequately characterized at the transcriptomic level in colorectal cancer (CRC), and its clinical implications are not yet fully understood. Methods: We integrated transcriptomic datasets from TCGA-COAD/READ and two independent GEO cohorts (GSE40967 and GSE87211) to develop an RNA-seq–based ITH score using the DEPTH2 algorithm and to con0struct an ITH-related gene (ITRG) prognostic model. A unified cutoff value of 0.64 was established to stratify patients into high- and low-ITH groups. Using 52 survival-associated ITRGs, we generated a nine-gene prognostic signature selected from 101 distinct combinations of feature selection techniques and modeling algorithms and validated its performance in two external datasets. The tumor microenvironment and potential responsiveness to immune checkpoint inhibitors were evaluated using ssGSEA, ESTIMATE, and TIDE algorithms. SHAP analysis, together with in vitro and in vivo experiments, was employed to identify and functionally validate key regulatory genes. Results: Patients in the high-ITH group had markedly poorer overall survival (OS) than those in the low-ITH group. The ITH score correlated strongly with aggressive clinical features, including T3/4 invasion depth, N1/2 nodal status, and AJCC stage III. The nine-gene prognostic signature demonstrated consistent predictive capability across the TCGA training cohort and both GEO validation cohorts. In TCGA, the model yielded time-dependent AUCs of 0.669, 0.664, and 0.645 for 1-, 3-, and 5-year OS, respectively, and retained its status as an independent prognostic indicator in multivariate Cox regression analysis; in GSE40967 and GSE87211, the corresponding AUCs ranged from 0.544–0.573 and 0.648–0.744. The high-risk subgroup was characterized by a stromal immune phenotype enriched with cancer-associated fibroblasts and macrophages, elevated expression of multiple immune checkpoints, increased TIDE scores, and higher tumor mutational burden. SHAP analysis identified IL20RB as the top risk-associated gene, whose knockdown significantly suppressed CRC cell proliferation, migration, invasion, and tumorigenicity in vitro and in vivo . Conclusion: This study introduces and validates a transcriptomic ITH score and a nine-gene ITRG-based prognostic model that delineate the immune landscape and enables effective survival stratification in CRC, complementing the limitations of current staging systems. Additionally, IL20RB is highlighted as a promising therapeutic target, supporting the development of personalized immuno-targeted combination therapies in CRC.
- 3 January 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 171, 116158
Multi-omics analysis identifies a glycosyltransferase-related prognostic signature linked to the immune landscape in colorectal cancer
- 3 January 2026
- Published by Elsevier in International Immunopharmacology
- Vol. 171, 116158
Multi-omics analysis identifies a glycosyltransferase-related prognostic signature linked to the immune landscape in colorectal cancer